从创新药研发到国际合作，中国生物医药产业正迎来加速发展的新阶段。那么，中国能否诞生世界级生 物医药企业，需要达到哪些条件？ 在11月13日召开的上海证券交易所国际投资者大会上，多位生物医药上市公司高管认为，中国生物医药 企业要达到世界级水平，不仅需要业绩达到一定规模，还需要在相关领域具备核心竞争力与较高壁垒， 获得国际市场认可，当然过程中存在挑战，但中国一定会出现世界级生物医药企业。 生物医药企业出海已从过去的 "可选之路" 转变为 "必由之路"，成为当下行业发展的一大核心趋势。那 么中国生物医药企业出海过程中遇到哪些挑战？在上述高管看来，出海过程中，遇到比较大的挑战是国 际环境的不确定性、地方保护主义等。 成为世界级生物医药企业应具备哪些条件？ 中国能否诞生世界级的生物医药企业，中国企业与世界一流企业之间存在怎样的差距，成为市场的一大 讨论点。 "从国际化角度来说，我们还在打基础，还在建立基础。从新分子实体角度来说，已经证实恒瑞可以做 创新，可以产生较多创新产品。"恒瑞医药（600276.SH）全球研发总裁张连山说，下一步将这些数量向 质量进一步提升，打造一个更好的出海基础和渠道。 张连山同时称，中国创新药 ...

Core Insights - Heptares Therapeutics recently held a global R&D day in Shanghai, where it officially launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ artificial intelligence platform [1] - The model is based on Heptares' proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, this platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1] Industry Developments - During the event, the AI + Biopharmaceutical Ecosystem Alliance was officially launched, with members including Foton Capital, Insilico Medicine, Molecular Heart, Aweilo Medical Technology, Innovent Biologics, Fenglin Group, Taimi Medical, Yilinyun, Deep Intelligence, and Heptares Therapeutics [1]

开栏语：今年以来，浙江省以"人工智能+"行动为牵引，杭州市全力打造人工智能创新发展高地，各地 全力竞逐人工智能新赛道。钱塘（新）区勇担使命，立足区内雄厚的产业基础与创新沃土，精准聚焦 AI医药、具身智能、高端芯片三大特色赛道，加速布局未来产业，汇聚创新动能。《AI聚钱塘 智创新 高地》今日开栏，旨在深入一线，解读产业布局、追踪技术突破、展示前沿成果，生动诠释以科技创新 为核心的新质生产力，向您呈现一个活力奔涌的钱塘新图景。 在今年8月钱塘举办的"AI+生物医药"创新研讨会上，浙大智药院副院长曹戟表示，类似的技术攻坚在 钱塘已经上演了200多次，目前浙大智药研究院在钱塘已与安域生物、歌礼生物等15家企业共建联合研 发中心，并成功孵化禹泓医药等7家医药企业，承接项目140余项。 "研究院为我们提供从靶点确证、分子优化到非临床评价的全链条，"禹泓医药负责人表示，"YH001项 目快速推进至临床Ⅱ期，帮助我们完成了超过1亿元的融资，企业估值已达准独角兽标准。" 产业集群崛起，筑牢高质量发展根基 随着高能级平台赋能效应持续释放，钱塘生物医药产业已实现从 "企业单点突破"到 "集群协同发展"的 跨越，构建起覆盖研发、生产 ...

"全程绿灯"加速好药上市步伐 今年8月，《中国（江苏）自由贸易试验区生物医药全产业链开放创新发展方案》获得国务院批复并正 式发布。9月16日，省政府召开新闻发布会，深度解读该方案背后的"首创性"与"集成性"，以3个关键词 勾勒出江苏生物医药产业开放创新的新蓝图：从实验室研发到临床使用全流程加速，让"好药"研发、通 关、使用环节实现"全程绿灯"；从全球高端人才到跨境数据资源自由流通，让百姓在家门口就能挂上外 籍专家号……这场覆盖全链条的改革实践，让"江苏造"创新药离市场更近，更快造福患者，折射民生温 度。 该方案以问题为导向，在流程效率、资源配置、创新生态等关键领域实现突破性进展，让政策红利真正 看得见、摸得着、用得上。 "方案自酝酿之初，就坚持以解决企业的困难诉求为制度创新的出发点和突破口。文件的起草过程，就 是帮助企业解决问题的过程。"司勇举例说，方案第9条"进出境实验动物监管模式改革"便源于企业困 境。省内一家基因工程小鼠企业，其携带人类基因的实验小鼠是新药研发关键模型动物，因携带人类遗 传物质，此前需接受特殊物品与实验动物出口双重监管，通关耗时久。但小鼠生命周期短，常未完成监 管就长成成年鼠，丧失实验价 ...

Core Insights - The "Jiangsu Free Trade Zone Biopharmaceutical Industry Chain Open Innovation Development Plan" was approved by the State Council, aiming to accelerate the entire process from laboratory research to clinical use, facilitating faster access to innovative drugs for patients [1][2] - The plan emphasizes "full-chain reform, institutional openness, and high-level innovation" to address pain points in the biopharmaceutical industry, with 18 specific measures across six key areas [2][5] Full-Chain Reform - The plan aims to enhance research and innovation capabilities, improve approval services, build production and circulation systems, refine procurement policies, increase resource guarantees, and maintain safety standards [2][5] - Jiangsu's biopharmaceutical industry accounts for 1/8 of the national scale, with 1/3 of innovative drugs approved, indicating its leading position in the country [2][6] - Specific reforms include expediting the approval process for generic drugs, reducing fixed asset investment by 30% through segmented production, and eliminating barriers for innovative drugs to reach the market [2][5] Institutional Openness - The plan allows foreign professionals with recognized qualifications to work in Jiangsu without needing to pass domestic exams, facilitating access to international medical expertise for local residents [3][5] - The management of outbound data will see a reduction in evaluation time by 30%-50%, enhancing cross-border data flow for research [3][5] High-Level Innovation - Focus areas include gene and cell therapy, brain science, and the establishment of platforms like the National Biopharmaceutical Technology Innovation Center [3][4] - The plan encourages companies to participate in standard-setting and broadens financing channels through credit bonds [3][4] Addressing Industry Bottlenecks - The plan is problem-oriented, targeting key areas such as process efficiency and resource allocation to ensure tangible benefits for enterprises [5][6] - For instance, reforms in the regulation of experimental animals aim to reduce export clearance times by approximately 50%, addressing specific challenges faced by companies [5][6] Ensuring Effective Reform - Jiangsu will implement measures to ensure that reforms transition from paper to practice, focusing on regional collaboration and detailed management [7] - The plan includes a task list to clarify responsibilities and timelines, ensuring that the 18 measures are effectively executed [7]

今年8月，《中国（江苏）自由贸易试验区生物医药全产业链开放创新发展方案》获得国务院批复 并正式发布。9月16日，省政府召开新闻发布会，深度解读该方案背后的"首创性"与"集成性"，以3个关 键词勾勒出江苏生物医药产业开放创新的新蓝图：从实验室研发到临床使用全流程加速，让"好药"研 发、通关、使用环节实现"全程绿灯"；从全球高端人才到跨境数据资源自由流通，让百姓在家门口就能 挂上外籍专家号……这场覆盖全链条的改革实践，让"江苏造"创新药离市场更近，更快造福患者，折射 民生温度。 三大关键词锚定"全链创新" 该方案以"全链条改革、制度型开放、高水平创新"为核心骨架，系统构建起覆盖生物医药产业研 发、生产、流通、使用全周期的创新体系，每个关键词都精准破解产业发展痛点。 "一条链的改革，贯通6个方面18项政策集成。"省商务厅厅长司勇介绍，方案从增强研发创新能 力、提升审批服务水平、构建生产流通体系、完善采购使用政策、加大要素保障、守牢安全底线6个方 面，细化18项举措，核心目标是为国家探制度、为江苏赋动能、为企业解难题。 "全链条改革"立足优势精准破局。江苏生物医药产业规模占全国1/8，创新药获批数占1/3，均居全 国 ...

Group 1: AI and Biopharmaceutical Innovation - The establishment of the Jiangsu Provincial Artificial Intelligence Biopharmaceutical Technology Industry Research Institute aims to address critical challenges in the biopharmaceutical industry by integrating top talent and innovative collaboration mechanisms [1][2] - The research institute has gathered over 600 top scholars and more than 60 member organizations, focusing on transforming research outcomes from laboratories to production lines [1][2] - The institute has developed high-end facilities, including a 300kV cryo-electron microscope, to facilitate collaborative research among over 20 units, including universities and pharmaceutical companies [1] Group 2: Structural Challenges in Biopharmaceutical Industry - The research institute's development is driven by a dual approach of "expert leadership + mechanism innovation" to enhance the integration of industry, academia, and research [2] - The institute has achieved significant breakthroughs, such as the discovery of the complete structure of miRNA in human serum, which won the second prize in the 2024 National Natural Science Award [2] - Collaborations with companies like Huawei to create foundational models for drug development demonstrate the institute's commitment to providing technical support for the industry [2] Group 3: Integrated Circuit Industry Development - The successful launch of the first domestically produced 28nm electron beam measurement equipment by Wuxi Changdian Technology fills a gap in China's integrated circuit industry and enhances the autonomy of domestic chip manufacturing [3] - Wuxi has developed a collaborative ecosystem in the integrated circuit industry, with a cluster scale exceeding 250 billion yuan, ranking second nationally in output value [3] - The integration of technological innovation and equipment development has strengthened the competitiveness of companies in the global integrated circuit packaging and testing sector [3] Group 4: Technology and Industry Integration - The organization of industry-academia-research cooperation conferences aims to facilitate seamless connections between innovation chains and industry chains, accelerating the transformation of scientific achievements into productive forces [4] - Jiangsu Province has produced over 200 landmark achievements in industrial technology innovation, primarily in fields such as artificial intelligence, biopharmaceuticals, integrated circuits, and new materials [4]

Group 1 - The core viewpoint of the articles emphasizes the integration of AI in the biopharmaceutical industry, highlighting its potential to enhance efficiency, precision, and safety in drug development [1][2][4] - The global biopharmaceutical R&D faces challenges such as a 10-year development cycle, $1 billion investment, and less than 10% success rate, which AI is positioned to address through advanced data processing and predictive modeling [2][3] - Zhejiang University’s Intelligent Innovation Drug Research Institute has successfully incubated 7 companies and undertaken over 140 projects, addressing more than 200 critical issues faced by enterprises [2][4] Group 2 - Derui Zhiyuan, a key biopharmaceutical company in Qiantang, utilizes AI to reconstruct drug development pathways, significantly reducing the time and cost associated with identifying effective drug candidates [3][4] - Qiantang has established a robust biopharmaceutical ecosystem with over 1,800 companies and more than 500 high-end talents, including major global pharmaceutical firms and "quasi-unicorn" enterprises [4][5] - Pfizer's Smart Medical Innovation Center has been established in Qiantang, focusing on innovative digital solutions and improving patient quality of life, leveraging the region's strong digital and innovative capabilities [5][6]

Core Viewpoint - The 2025 World Artificial Intelligence Conference (WAIC) in Shanghai highlighted the significant role of AI in accelerating drug development and transforming the healthcare ecosystem, with a focus on innovation in the pharmaceutical industry [1][4]. Industry Insights - AI technology is rapidly evolving, enabling faster analysis of vast medical data, predicting drug efficacy, and shortening drug development cycles while reducing costs [1][4]. - The global pharmaceutical landscape is undergoing a transformation, with multinational companies increasingly sourcing innovative drugs from China, driven by supportive domestic policies and steady clinical advancements [1][4]. - The innovative drug sector has shown strong performance, with the Wind Innovation Drug Index rising by 48.51% and the Hong Kong Innovation Drug Index increasing by 104.51% as of July 31, 2025 [3]. Company Performance - The performance of the Noan Selected Value Mixed Fund has been notable, with a net value growth rate of 61.88% over the past six months, significantly outperforming its benchmark of 5.74% [3]. - The fund's strategy has focused on the undervaluation of the pharmaceutical sector, with a balanced investment approach in both Hong Kong and A-share markets [3][4]. - The establishment of the "Technology Group" by Noan Fund in 2020 reflects a proactive approach to building a diverse product matrix in the technology investment space [4]. Technological Advancements - Modern surgical robots are enhancing surgical precision by analyzing real-time data and providing feedback, which reduces risks and improves success rates [2]. - The rise of remote surgery, facilitated by 5G/6G networks, allows surgeons to operate on patients from thousands of kilometers away, improving access to healthcare in remote areas [2].

Core Insights - The article highlights the rapid advancements in AI-driven drug development in Hangzhou, particularly in the Qiantang (New) District, which is becoming a hub for the integration of AI and biomedicine [4][6][8] Group 1: AI in Drug Development - Derui Zhiyao's first AI-designed oral small molecule drug, MDR-001, has successfully entered clinical trials, offering new treatment options for overweight patients [4] - The company has developed a one-stop drug research and development platform, Molecule Pro™, which significantly reduces the time and cost of drug development by 50% and saves 1.5 to 3 years compared to traditional methods [6][7] - The Zhejiang University Intelligent Innovation Drug Research Institute has been instrumental in supporting local pharmaceutical companies with AI technology, leading to the incubation of seven drug companies in the Qiantang area [7][8] Group 2: Industry Growth and Investment - Qiantang District has established a comprehensive ecosystem for biomedicine, including preclinical research, clinical trial platforms, and full-chain industrialization processes [9] - The district's industrial fund has exceeded 45 billion yuan, with investments in 266 companies, including 71 unicorns, showcasing strong financial backing for the biomedicine sector [9] - Recent discussions at the Zhejiang Provincial High-level Talent Conference highlighted the potential of AI in transforming biomedical understanding and practices, indicating a forward-looking approach to industry development [8][9]